Amgen At A Crossroads: Analysts Question Capital Allocation, M&A,D-mab
Executive Summary
Amgen Inc. is going through a transformational time as many of its top-selling drugs are maturing and its latest potential blockbuster franchise tries to find a foothold in the market. While Prolia/Xgeva (denosumab) offers a lucrative lifeline for the big biotech, investors are getting anxious about the company’s future; pushing for a dividend and for clarity about its strategy.
You may also be interested in...
A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline
Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.